Table 1.
Overview of studies on MR-HIFU for painful bone metastases
| Study | Patients | Primary tumour (n) | Location (n) | Average duration, min (range) | Average no. of sonications (range) | No. of patients with 3-month follow-up (%) | Pain responsea |
|---|---|---|---|---|---|---|---|
| Catane et al. (2007)[24] | 13 (14 lesions) | Breast (4) | Ilium (10) | 80 (22–158) | 29 (11–39) | 11/13 (85) | 3 days after treatment: improvement in most cases |
| Prostate (2) | Ischium (1) | ||||||
| Lung (1) | Sacrum (1) | 3 months after treatment: improvement in both pain score and dosage of pain-reducing medication | |||||
| Renal (1) | Humerus (1) | ||||||
| Colorectal (1) | Femur (1) | ||||||
| Other (4) | |||||||
| Gianfelice et al. (2008)[25] | 11 (12 lesions) | Breast (5) | Ilium (7) | 28–103 | 12–18 | 11/11 (100) | 3 days after treatment: OR=73% and CR=9% |
| Renal (4) | Ischium (1) | ||||||
| Lung (1) | Scapula (2) | 1 month after treatment: OR=91% and CR=27% | |||||
| Liver (1) | Clavicula (1) | 3 months after treatment: OR=100% and CR=45% | |||||
| Liberman et al. (2008)[26] | 31 (32 lesions) | Breast (11) | Ilium (18) | 66 (22–162) | 17.3 (8–32) | 25/31 (81) | 3 months after treatment: OR=72% and CR=36% |
| Renal (6) | Ischium (4) | ||||||
| Prostate (5) | Sacrum (4) | ||||||
| Colorectal (2) | Femur (1) | ||||||
| Lung (1) | Scapula (2) | ||||||
| Other (6) | Humerus (1) | ||||||
| Clavicula (1) |
Abbreviations: OR, overall response; CR, complete response.
aThe listed response rates are derived from the articles using the Update of the International Consensus on Palliative Radiotherapy Endpoints for Future Clinical Trials in Bone Metastases[37]. OR is defined as pain score of 0 without analgesic increase; CR is defined as pain reduction ≥2 without analgesic increase or analgesic reduction ≥25% without pain increase.